Cooling Down Stroke Damage: A New Approach to Brain Recovery
"Can targeted hypothermia combined with clot removal offer hope for better outcomes after severe stroke?"
When a major artery in the brain becomes blocked, cutting off vital blood flow, the result is an acute ischemic stroke. The current standard of care involves quick action: administering intravenous tissue plasminogen activator (tPA) to dissolve the clot and/or performing an endovascular thrombectomy to physically remove it. However, even when these treatments successfully restore blood flow, some patients still experience significant brain damage and limited recovery.
The problem? Ischemia/reperfusion (I/R) injury. This occurs when blood flow returns to the oxygen-starved tissue, paradoxically causing further damage. Scientists have been exploring ways to protect the brain from this secondary injury, and one promising avenue is hypothermia, or targeted cooling. The idea is that lowering the brain's temperature can reduce the harmful effects of I/R injury.
Now, a clinical trial is underway to investigate the safety of combining endovascular thrombectomy with regional transarterial hypothermic infusion – essentially, delivering cool saline directly to the affected area of the brain. This article breaks down the study's protocol and explores how this innovative approach could potentially improve outcomes for acute ischemic stroke patients.
Stroke’s Burden and Hypothermia’s Promise
Acute ischemic stroke is a leading cause of death and disability worldwide. Therapeutic hypothermia has long been considered a strong neuroprotective strategy, and it is used for neuroprotection after cardiac arrest. However, although benefits have been demonstrated in cardiac arrest and neonatal hypoxic-ischemic encephalopathy, a benefit in stroke has not yet been convincingly demonstrated.
Cooling Strategies and Evidence Gaps
Systemic therapeutic hypothermia for acute ischemic stroke has been described as lowering body and/or brain temperature to 32–34°C for 12–24 hours. The ICTuS-L study showed that endovascular cooling to 33°C could be combined with standard thrombolytic therapy. However, the reviewed studies had not shown reduced mortality after ischemic stroke, and larger patient groups were considered necessary to evaluate efficacy.
The Cooling Protocol: How It Works
The study focuses on patients experiencing acute ischemic stroke with a blockage in a major cerebral artery who are eligible for endovascular thrombectomy. The key inclusion criteria include a moderate to severe stroke as indicated by a National Institutes of Health Stroke Scale (NIHSS) score of 5-29. Importantly, even if patients are already taking oral anticoagulants or antiplatelet medications, they are still eligible for the trial.
- Rapid Assessment: Upon arrival at the hospital, patients undergo immediate assessment, including cerebral MRI and MR angiography (MRA) or CT scans, to confirm the stroke and identify the location of the blockage.
- Standard Treatment: Eligible patients receive intravenous tPA to begin dissolving the clot. If the artery remains blocked, endovascular thrombectomy is performed.
- Hypothermic Infusion: If, after successful clot removal, the patient shows no improvement in their NIHSS score, the cooling intervention begins. Cold saline (15°C) is administered through a microcatheter placed in the internal carotid artery on the same side as the stroke. The saline is delivered at a rate of 10mL/min for 10 minutes, totaling 100mL.
- Close Monitoring: Throughout the procedure, the patient's vital signs and neurological status are carefully monitored for any adverse reactions.
Selective Cooling and Reperfusion
Research on selective intra-arterial cooling notes that meaningful cooling may be possible when infusion occurs distal to an occlusion, where blood does not mix with the infusate as it exits the catheter. Intra-arterial cooling may be less effective when cerebral perfusion is compromised, but may be a viable option after reperfusion in patients with large-vessel occlusion ischemic stroke. Separately, a review reports that cognitive disturbance is common after stroke and that cognitive function is an important focus of stroke rehabilitation.
Unproven Benefit and Trial Design Needs
A review concludes that, despite strong evidence for therapeutic hypothermia after cardiac arrest and in neonatal hypoxic-ischemic encephalopathy, its benefits have not been shown in ischemic stroke. A clinical-trial protocol describes plans for a larger follow-up study, with patients stratified by symptom severity, including baseline NIHSS score. Another review advocates continued clinical translation of intra-arterial selective cooling in the era of reperfusion, reflecting that the approach remains under investigation.
Why This Trial Matters: Potential and Future Directions
This clinical trial is an essential first step in evaluating a novel approach to stroke treatment. The primary goal is to confirm the safety of regional transarterial hypothermic infusion when combined with standard endovascular thrombectomy. Researchers will carefully track mortality, morbidity, and any adverse events.
Strong Experimental Rationale, Uncertain Stroke Role
Mild hypothermia has produced consistent neuroprotective effects across laboratory models and multiple kinds of brain injury. Clinical benefits have been reported for comatose survivors of cardiac arrest and some pediatric patients with hypoxic brain insults. Yet its role in stroke therapy remains unresolved, even though a systematic review and meta-analysis of animal ischemic-stroke studies found reduced infarct size and improved neurological outcomes.
Clarifying Clinical Application
A review published May 30, 2025, describes therapeutic hypothermia as a promising neuroprotective strategy but says its use in acute ischemic stroke remains unclear because clinical outcomes vary between bench research and bedside application. The review reports that it drew on original studies identified through PubMed, Web of Science, and Embase. A January 15, 2026, review also focuses on targeted temperature management, including hypothermia therapy, in acute ischemic stroke.
A Promising Strategy Beyond Stroke
A 2024 review describes acute ischemic stroke as a major contributor to mortality and disability worldwide. It characterizes hypothermia as a promising neuroprotective strategy, with established effectiveness in cardiac arrest and neonatal hypoxic-ischemic injury. The review examines its therapeutic potential in ischemic stroke through its effects on the poststroke brain.
If the procedure proves safe, the next step would be a larger clinical study to determine its effectiveness. This future trial could assess whether the cooling intervention leads to improved neurological outcomes, reduced brain damage, and enhanced recovery for stroke patients.
Ultimately, this research could pave the way for a significant shift in stroke treatment, offering a new strategy to minimize the devastating effects of I/R injury and improve the lives of those affected by this condition.